Priority topics

Areas covered will include:

• Long COVID, post ICU syndrome and rehabilitation.
• Patients with overlapping lung diseases: clinical management and challenges.
• Lung function testing during the COVID-19 pandemic and beyond.
• Holistic management and rehabilitation of fibrosing interstitial lung diseases.
• Maintenance of pulmonary rehabilitation benefits and role of digital health.

Areas covered will include:

• Weaning from mechanical ventilation: lessons from WEAN-SAFE.
• ERS Statement on dyspnea in acutely ill mechanically ventilated patients.
• Lung ultrasound in acute respiratory care.
• Advanced care planning in long-term mechanical ventilation.
• Setting up chronic ventilation: what are the needs for different diseases?

Areas covered will include:

• Lung tissue regeneration and repair.
• Cell death modalities in chronic lung diseases affecting inflammation, autophagy, fibrosis and senescence.
• Fundamentals of alveolar cell function.
• Exposure-driven damage of the lung, including: microplastics, diesel exhaust, biomass fuels, e-cigarettes, climate change.
• Effects of long COVID and fatigue on lung biology.

Areas covered will include:

• Myth or reality: is obstructive sleep apnoea really critical for cardiovascular complications? Does PAP treatment improve cardiovascular outcome? Limitations and strengths of large-sized trials, what is needed for the future.
• New technologies in Sleep-disordered breathing diagnosis: one metric doesn’t fit all. Polysomnography, polygraphy (Typ-III devices), non-classical sensors: which parameters really matter? How can we diagnose more focused to the patient’ requirements?
• The multi-components of obstructive sleep apnoea pathophysiology: from mechanics to hypoxic burden and intracellular mechanisms.
• Residual daytime sleepiness: systematic analysis, treatment algorithm and the role of pharmaceutical agents.
• More than obstructive sleep apnoea and central sleep apnoea: hypoventilation syndromes from identification to treatment and follow-up.

Areas covered will include:

• What is around the corner? New drugs in airways disease.
• Precision medicine approaches in airway disease.
• Updates in asthma management and treatment.
• Updates on new biomarkers in airway disease.
• Updates in the management and treatment of COPD.

Areas covered will include:

• Respiratory health effects of low air pollution exposures.
• Epidemiology as a digital tool for the improvement of public health.
• Respiratory epidemiology from distribution, patterns and determinants of respiratory diseases to evidence-based practice.
• Greenness, blueness and respiratory health.
• Digital tools for improving asthma control across disease severity.

Areas covered will include:

• Asthma: advances in diagnosis and management of acute asthma attacks, novel approaches to improve adherence in asthma.
• Severe asthma in children.
• Impact of COVID-19 in children with respiratory diseases.
• Microbial manipulation in the treatment and prevention of asthma.
• Phenotypes of bronchopulmonary dysplasia.

Areas covered will include:

• Lung transplantation in patients not recovering from ARDS (including COVID-19): ethics, indications, pitfalls and outcomes.
• Ground glass opacities after COVID pandemic: a new challenge for the thoracic oncology multidisciplinary team management.
• Current treatment options in CVD-ILD: from immunosuppression to anti-fibrotics and transplantation.
• Is surgery for stage IV-M1a lung cancer justified?
• Integrating artificial intelligence and innovative techniques in the management of chest malignancies.

Areas covered will include:

• Assessment of respiratory function using digitised technology.
• Utilising exercise testing in pre-operative assessment, rehabilitation and exercise prescription.

Areas covered will include:

• New antimicrobial strategy.
• Transmission of respiratory infections. Should we rethink mass gatherings?
• Respiratory infections in healthcare settings. What have we learned? Are we prepared?
• Respiratory infection in the immunocompromised host: from prevention to diagnosis and treatment
• Promises and advances in tuberculosis diagnostic, treatment and prevention (UNITE4TB).

Areas covered will include:

• Lung cancer screening: update 2022.
• Multidisciplinary team management in thoracic oncology V4.0.
• Multidisciplinary care of stage III non-small-cell lung carcinoma.
• Diagnostic-therapeutic sequences in lung cancer.
• Differential diagnoses/management of pulmonary nodules.

Areas covered will include:

• Connective tissue diseases and the lung.
• Novel insights into the diagnosis of fibrosis.
• Idiopathic pulmonary fibrosis: from bench to bedside.
• Fibrosis and lung cancer.
• Pulmonary hypertension in fibrotic lung diseases; to treat or not to treat.

Areas covered will include:

• Novel treatment targets in pulmonary arterial hypertension.
• From chronic thromboembolic disease to chronic thromboembolic pulmonary hypertension: diagnosing and treating symptoms after acute pulmonary embolism.
• The hemodynamic definition of pulmonary hypertension at rest and exercise.
• Novel imaging techniques in pulmonary hypertension.
• Understanding low diffusion capacity in pulmonary arterial hypertension.

Areas covered will include:

• Interventional pulmonology.
• Interventional pulmonology workstations.
• Transbronchial (cryo)biopsy and surgical lung biopsy in interstitial lung diseases.
• Ultrasound.
• Endobronchial ultrasound (EBUS)/ Esophageal ultrasound with ultrasound bronchoscope (EUS-B).